Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats

Cancer Research

Volumn 57, Issue 7, 1997, Pages 1288-1293

  Davies, Reginald ^a   Oreffo, Victor I C ^a   Martin, Elizabeth A ^a   Festing, Michael F W ^a   White, Ian N H ^a   Smith, Lewis L ^a   Styles, Jerry A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; TOREMIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASE PAIRING; CANCER RISK; CHEMICAL MUTAGENESIS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA ADDUCT; GENE MUTATION; GENOTOXICITY; LIVER CANCER; NONHUMAN; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL;

AFLATOXINS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DNA ADDUCTS; FEMALE; LIVER; MUTAGENICITY TESTS; MUTAGENS; RATS; RATS, INBRED F344; TAMOXIFEN; TOREMIFENE;

EID: 0030999951     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Jordan, V. C. Overview from the international conference on long-term tamoxifen therapy for breast cancer. J. Natl. Cancer Inst., 84: 231-234, 1992.
2. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J., and Orton, T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53: 3919-3924, 1993.
3. Hard, G., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53: 4534-4541, 1993.
4. Tucker, M. J., Adam, H. K., and Patterson, J. S. Tamoxifen. Safety Testing of New Drugs. (D. R. Laurence, A. E. M. McLean, and M. Weatherall, eds.), pp. 125-161. New York: Academic Press, 1984.
5. Styles, J. A., White, I. N. H., Blowers, S., and Phillips, B. Studies on the mutagenicity of tamoxifen. Toxicologist, 13: 223, 1993.
6. Carthew, P. , Martin, E. A., White, I. N. H., DeMatteis, F., Edwards, R. E., Dorman, B. M., Heydon, R. T., and Smith, L. L. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res., 55: 544-547, 1995.
7. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis (Lond.), 16: 1299-1304, 1995.
8. Han, X., and Liehr, J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52: 1360-1363, 1992.
9. White, I. N. H., DeMatteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis (Lond.), 13: 2197-2203, 1992.
10. Sargent, L. M., Dragan, Y. P., Bahnub, N., Wiley, J. E., Sattler, C., Schroeder, P., Sattler, G. L., Jordan, V. C., and Pilot, H. C. Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res., 54: 3357-3360, 1994.
11. Sargent, L. M., Dragan, Y. P., Sattler, C., Bahnub, N., Sattler, G. L., Martin, P., Cisneros, A., Mann, J., Thorgeirsson, S., Jordan, V. C., and Pilot, H. C. Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis (Lond.), 17: 1051-1056, 1996.
12. Kohler, S. W., Provost, G. S., Fieck, A., Kretz, P. L., Bullock, W. O., Sorge, J. A., Putman, D. L., and Short, J. M. Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc. Natl. Acad. Sci. USA, 88: 7958-7962, 1991.
13. Provost, G. S., Kretz, P. L., Hamner, R. T., Matthews, C. D., Rogers, B. J., Lundberg, K. S., Dycaico, M. J., and Short, J. M. Transgenic systems for in vivo mutation analysis. Mut. Res., 288: 133-149, 1993.
14. Mirsalis, J. C., Monforte, J. A., and Winegar, R. A. Transgenic animal models for measuring mutations in vivo. Crit. Rev. Toxicol., 24: 255-280, 1994.
15. Gorelick, N. J. Overview of mutation assays in transgenic mice for routine testing. Environ. Mol. Mutagen., 25: 218-230, 1995.
16. Kangas, L. Review of the pharmacological properties of toremifene. J. Steroid Biochem., 36: 191-195, 1990.
17. 14C]tamoxifen and toremifene in rats. Proc. Am. Soc. Cancer Res., 37: 373, 1996.
18. 1. Carcinogenesis (Lond.), 17: 2347-2356, 1996.
19. Ushijima, T., Hosoya, Y., Suzuki, T., Sofuni, T., Sugimura, T., and Nagao, M. A rapid method for detection of mutations in the lacI gene using PCR-single stranded conformational polymorphism analysis. Mut. Res., 334: 283-292, 1995.
20. Eaton, D. L., and Gallagher, E. P. Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 34: 135-172, 1994.
21. Dycaico, M. J., Provost, G. S., Kretz, P. L., Ransom, S. L., Moores, J. C., and Short, J. M.. The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mut. Res., 307: 461-478, 1994.
22. Mirsalis, J. C., Provost, G. S., Matthews, C. D., Hamner, R. T., Schindier, J. E., O'Loughlin, K. G., MacGregor, J. T., and Short, J. M. Induction of hepatic mutations in lacI transgenic mice. Mutagenesis, 8: 265-271, 1993.
23. Monison, V., and Ashby, J. A preliminary evaluation of the performance of the Muta™ Mouse (lacZ) and Big Blue™ (lacI) transgenic mouse mutation assays. Mutagenesis, 9: 367-375, 1994.
24. Ushijima, T., Hosoya, Y., Ochiai, M., Kushida, H., Wakabayashi, K., Suzuki, T., Hayashi, M., Sofuni, T., Sugimura, T., and Nagao, M. Tissue-specific mutational spectra of MeIQ in the liver and bone marrow of lacI transgenic mice. Carcinogenesis (Lond.), 15: 2805-2809, 1995.
25. Osborne, M. R., Hewer, A., Hardcastle, I. R., Carmichael, P. L., and Phillips, D. H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56: 66-71, 1996.
26. Loeb, L. A., and Preston, B. D. Mutagenesis by apurinic/apyrimidinic sites. Ann. Rev. Genet., 20: 201-230, 1986.
27. Chakravarti, D., Felling, J. C. Cavalieri, E. L., and Rogan, E. G. Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: the role of apurinic sites. Proc. Natl. Acad. Sci. USA, 92: 10422-10426, 1995.
28. Vancutsem, P. M., Lazarus, P., and Williams, G. M. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res., 54: 3864-3867, 1994.
29. 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis (Lond.), 16: 1651-1654, 1995.
30. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fomander, T., and Wilking, N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl. Cancer Inst., 87: 645-651, 1995.
31. Walker, V. E., Gorelick, N. J., Andrews, J. L., Craft, T. R., deBoer, J. G., Glickman, B. W., and Skopek, T. R. Frequency and spectrum of ethylnitrosourea-induced mutation at the hprt and lacI loci in splenic lymphocytes of exposed lacI transgenic mice. Cancer Res., 56: 4654-4661, 1996.
32. Lerner, L. J., and Jordan, V. C. Development of antiestrogens and their use in breast cancer. Cancer Res., 50: 4177-4189, 1990.
33. Early Breast Cancer Trialists Collaborative Group, Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet, 339: 1-14, 1992.
34. Grainger, D. J., and Metcalfe, J. C. Tamoxifen: teaching an old drug new tricks. Nat. Med., 2: 381-385, 1996.